Your estimates are likely close Risk. I just liste
Post# of 30028
Posted On: 09/02/2014 8:12:44 PM
Re: Daveludlow #5373
Your estimates are likely close Risk. I just listened to the call and was very impressed with the team. I was really only concerned with listening to Lympro info on the first pass. The $150M was based off of the Phase 2 trials. Taking market share is one strategy, which taking a piece of the pie. AMBS could also potentially grow the pie. With a great test available, more trials may be started by BP, increasing the market size under CLIA.
You have attention to detail Risk. I thought I heard GC say they made a decision to present univariate data until CLIA submission. That would mean bridge data would be communicated as univariate again. Did you hear that?
You have attention to detail Risk. I thought I heard GC say they made a decision to present univariate data until CLIA submission. That would mean bridge data would be communicated as univariate again. Did you hear that?
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼